• Explore /
  • Poster
  • / IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.

IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.

Abstract Poster

Authors

null

Anthony W. Tolcher

START San Antonio, San Antonio, TX

Anthony W. Tolcher , David S. Hong , Ryan J. Sullivan , James Walter Mier , Geoffrey Shapiro , Joseph Pearlberg , Les H. Brail , Jahnavi Kharidia , Lixin Han , Claudio Dansky Ullmann , Howard Marvin Stern , Jedd D. Wolchok

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Other

Clinical Trial Registration Number

NCT02637531

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS3111)

DOI

10.1200/JCO.2016.34.15_suppl.TPS3111

Abstract #

TPS3111

Poster Bd #

425a

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Nicholas Coupe

First Author: Susanna Varkey Ulahannan

First Author: Charu Aggarwal